EU's stricter drug stockpiling rules Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 21 January, 2026

sponsored by #JPM26 Spotlights. Excellent Human-Monkey Cross-Reactivity. This CD3-VHH Potently Accelerates the Clinical Translation of TCE Drugs Overcome the species gap in preclinical TCE development. Fapon Biopharma's CD3-VHH exhibits excellent human-monkey cross-reactivity, enabling reliable safety & efficacy studies in NHP models. Ideal for bispecific/trispecific TCEs, in vivo CAR-T, and TCR-T therapies. Ready to de-risk and accelerate your program? Learn More

presented by A Psy­che­del­ic Re­nais­sance: How Defini­um Ther­a­peu­tics is Chang­ing How We Think about LSD and Treat Men­tal Health

news Think Bioscience gets $55M to unearth new drug pockets Fosun Pharma-funded biotech licenses Insilico’s NLRP3 inhibitor EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act

Catch up on all the sessions from Endpoints at #JPM26, including conversations with Novo Nordisk CEO Mike Doustdar and Nobel laureate Fred Ramsdell on where biopharma is heading next. Visit our on-demand hub to watch now.

ENDPOINTS PHARMA Government funding bill features PBM reforms, rare pediatric voucher reauthorization Valneva withdraws chikungunya vaccine from US after series of rare events US childhood vaccine overhaul spurs clinician groups to update lawsuit

Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Vice President, Investor Relations & Communications C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. Bioregnum 2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons 2. GSK makes $2.2B deal for RAPT and its food allergy candidate 3. News Briefing Aspect Bio takes Novo castoff therapies; Takeda trims US jobs 4. Corvus' new Phase 1 atopic dermatitis data meet high expectations 5. Isomorphic signs another pharma deal, partnering with J&J for AI-made drugs 6. Pfizer to depart GSK's ViiV as Shionogi doubles its stake 7. Exciva raises $59M to fund Phase 2 test of Alzheimer’s agitation drug 8. Google-backed Isomorphic Labs delays clinical trial timeline 9. This innovation saved lives in the pandemic. Now it’s showing strength against cancer.